Symbols / MRUS
MRUS Chart
About
Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes BIZENGRI for the treatment of patients with pancreatic adenocarcinoma or non-small cell lung cancer (NSCLC) and non Neuregulin 1. The company is also developing MCLA-158 for the treatment of solid tumors; MCLA-129 for the treatment of patients with lungs and other solid tumors; ONO-4685 to treat relapsed/refractory T cell lymphoma; and INCA33890 for advanced solid tumors. In addition, it has collaboration agreement with Eli Lilly and Company, Ono Pharmaceutical Co., Ltd., and Betta Pharmaceuticals Co. Ltd. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands. As of December 11, 2025, Merus N.V. operates as a subsidiary of Genmab A/S.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 6.83B |
| Enterprise Value | 6.20B | Income | -381.14M | Sales | 56.61M |
| Book/sh | 10.22 | Cash/sh | 8.38 | Dividend Yield | — |
| Payout | 0.00% | Employees | 260 | IPO | May 19, 2016 |
| P/E | — | Forward P/E | -17.65 | PEG | — |
| P/S | 120.59 | P/B | 8.81 | P/C | — |
| EV/EBITDA | -16.82 | EV/Sales | 109.57 | Quick Ratio | 7.59 |
| Current Ratio | 7.97 | Debt/Eq | 1.59 | LT Debt/Eq | — |
| EPS (ttm) | -5.28 | EPS next Y | -5.10 | EPS Growth | — |
| Revenue Growth | 3.20% | Earnings | 2026-02-26 | ROA | -26.53% |
| ROE | -51.57% | ROIC | — | Gross Margin | 36.99% |
| Oper. Margin | -7.94% | Profit Margin | 0.00% | Shs Outstand | 75.85M |
| Shs Float | 70.01M | Short Float | 1.08% | Short Ratio | 0.59 |
| Short Interest | — | 52W High | 97.14 | 52W Low | 33.19 |
| Beta | 1.06 | Avg Volume | 1.25M | Volume | 2.72M |
| Target Price | $97.00 | Recom | Hold | Prev Close | $90.00 |
| Price | $90.00 | Change | 0.00% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$97.00
Mean price target
2. Current target
$90.00
Latest analyst target
3. DCF / Fair value
$-41.40
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$90.00
Low
$97.00
High
$97.00
Mean
$97.00
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-10-06 | down | Leerink Partners | Outperform → Market Perform | $97 |
| 2025-09-30 | down | Guggenheim | Buy → Neutral | $97 |
| 2025-09-30 | down | Canaccord Genuity | Buy → Hold | $97 |
| 2025-09-30 | down | Wells Fargo | Overweight → Equal-Weight | $97 |
| 2025-09-30 | down | UBS | Buy → Neutral | $97 |
| 2025-09-30 | down | LifeSci Capital | Outperform → Market Perform | $97 |
| 2025-09-30 | down | Barclays | Overweight → Equal-Weight | $97 |
| 2025-09-30 | down | HC Wainwright & Co. | Buy → Neutral | $97 |
| 2025-09-29 | down | Truist Securities | Buy → Hold | $97 |
| 2025-09-29 | down | Wells Fargo | Overweight → Equal-Weight | $97 |
| 2025-09-29 | down | Needham | Buy → Hold | $96 |
| 2025-09-29 | down | Citigroup | Buy → Neutral | $97 |
| 2025-09-17 | init | Barclays | — → Overweight | $112 |
| 2025-08-25 | init | Alliance Global Partners | — → Buy | $90 |
| 2025-08-07 | main | Wells Fargo | Overweight → Overweight | $95 |
| 2025-08-06 | main | Needham | Buy → Buy | $96 |
| 2025-05-23 | main | BMO Capital | Outperform → Outperform | $110 |
| 2025-05-23 | main | Needham | Buy → Buy | $88 |
| 2025-05-19 | reit | Needham | Buy → Buy | $75 |
| 2025-05-08 | main | Wells Fargo | Overweight → Overweight | $89 |
- Merus N.V. (MRUS) Stock Analysis: Biotechnology Gem With 7.78% Potential Upside - DirectorsTalk Interviews Wed, 18 Feb 2026 03
- GMAB Stock Soars 21.9% in a Month Following MRUS Acquisition Deal - Yahoo Finance Mon, 06 Oct 2025 07
- Insider Sale: VP Controller of $MRUS Sells 8,300 Shares | MRUS Stock News - Quiver Quantitative Fri, 28 Nov 2025 08
- Genmab Announces Completion of Tender Offer for Outstanding Common Shares of Merus N.V. and Commencement of Subsequent Offering Period - Business Wire Fri, 12 Dec 2025 08
- Merus stock halted today as Genmab buyout closes: what happens to MRUS shares and the $97 cash payout - TechStock² ue, 30 Dec 2025 08
- Stocks making the biggest moves midday: CSX, Electronic Arts, Pony AI, Merus and more - CNBC Mon, 29 Sep 2025 07
- Merus (MRUS): Reassessing Valuation After a 120% Year-to-Date Rally and Strong Multi-Year Returns - simplywall.st Wed, 17 Dec 2025 08
- Genmab to acquire for $8B in cash (update) (GMAB:NASDAQ) - Seeking Alpha Sun, 28 Sep 2025 07
- Merus Shareholders Approve Genmab Acquisition Proposal - TipRanks ue, 09 Dec 2025 08
- Genmab stock price target raised to $32 from $24 at TD Cowen on MRUS deal - Investing.com ue, 30 Sep 2025 07
- Merus (MRUS) Sees Rating Downgrade and Target Price Raise by Wel - GuruFocus ue, 30 Sep 2025 07
- MRUS Surges: What’s Driving the Excitement? - StocksToTrade Mon, 29 Sep 2025 07
- MRUS Stock Soars 30% in 3 Months After Phase II Cancer Study Success - Yahoo Finance Fri, 11 Jul 2025 07
- Genmab Buys Merus For $8bn: A Good Deal If Potential Is Converted Into Revenue (MRUS) - Seeking Alpha Mon, 29 Sep 2025 07
- Why Merus NV Stock Skyrocketed Amid Acquisition News - TipRanks Mon, 29 Sep 2025 07
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 815444 | 79098068.0 | — | Purchase at price 97.00 per share. | GENMAB AS | Beneficial Owner of more than 10% of a Class of Security | — | 2025-12-26 00:00:00 | I |
| 1 | 278441 | 27008777.0 | — | Purchase at price 97.00 per share. | GENMAB AS | Beneficial Owner of more than 10% of a Class of Security | — | 2025-12-19 00:00:00 | I |
| 2 | 271547 | 26340059.0 | — | Purchase at price 97.00 per share. | GENMAB AS | Beneficial Owner of more than 10% of a Class of Security | — | 2025-12-17 00:00:00 | I |
| 3 | 1700 | 163370.0 | — | Sale at price 96.10 per share. | SHUMAN HARRY | Officer | — | 2025-11-26 00:00:00 | D |
| 4 | 1700 | 36875.0 | — | Conversion of Exercise of derivative security at price 18.61 - 24.43 per share. | SHUMAN HARRY | Officer | — | 2025-11-26 00:00:00 | D |
| 5 | 155757 | — | — | Stock Gift at price 0.00 per share. | LUNDBERG SVEN ANTE | Chief Executive Officer | — | 2025-11-25 00:00:00 | D/I |
| 6 | 8300 | 796136.0 | — | Sale at price 95.92 per share. | SHUMAN HARRY | Officer | — | 2025-11-25 00:00:00 | D |
| 7 | 8300 | 163353.0 | — | Conversion of Exercise of derivative security at price 13.23 - 24.61 per share. | SHUMAN HARRY | Officer | — | 2025-11-25 00:00:00 | D |
| 8 | 25000 | 1500000.0 | — | Sale at price 60.00 per share. | SILVERMAN PETER B. | Chief Operating Officer | — | 2025-07-17 00:00:00 | D |
| 9 | 25000 | 610750.0 | — | Conversion of Exercise of derivative security at price 24.43 per share. | SILVERMAN PETER B. | Chief Operating Officer | — | 2025-07-17 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 8.80M | -2.51M | 6.71M | 6.17M |
| TaxRateForCalcs | 0.26 | 0.26 | 0.26 | 0.25 |
| NormalizedEBITDA | -303.70M | -144.30M | -184.78M | -113.15M |
| TotalUnusualItems | 34.10M | -9.71M | 26.02M | 24.66M |
| TotalUnusualItemsExcludingGoodwill | 34.10M | -9.71M | 26.02M | 24.66M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -215.33M | -154.94M | -131.19M | -66.82M |
| ReconciledDepreciation | 2.47M | 2.54M | 1.28M | 1.49M |
| EBITDA | -269.60M | -154.01M | -158.75M | -88.49M |
| EBIT | -272.07M | -156.55M | -160.04M | -89.98M |
| NetInterestIncome | 30.79M | 14.51M | 2.72M | -129.00K |
| InterestExpense | 129.00K | |||
| InterestIncome | 2.72M | |||
| NormalizedIncome | -240.63M | -147.73M | -150.50M | -85.31M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -215.33M | -154.94M | -131.19M | -66.82M |
| TotalExpenses | 308.20M | 200.49M | 201.62M | 139.08M |
| TotalOperatingIncomeAsReported | -272.07M | -156.55M | -160.04M | -89.98M |
| DilutedAverageShares | 64.22M | 51.61M | 44.92M | 38.64M |
| BasicAverageShares | 64.22M | 51.61M | 44.92M | 38.64M |
| DilutedEPS | -3.35 | -3.00 | -2.92 | -1.73 |
| BasicEPS | -3.35 | -3.00 | -2.92 | -1.73 |
| DilutedNIAvailtoComStockholders | -215.33M | -154.94M | -131.19M | -66.82M |
| NetIncomeCommonStockholders | -215.33M | -154.94M | -131.19M | -66.82M |
| NetIncome | -215.33M | -154.94M | -131.19M | -66.82M |
| NetIncomeIncludingNoncontrollingInterests | -215.33M | -154.94M | -131.19M | -66.82M |
| NetIncomeContinuousOperations | -215.33M | -154.94M | -131.19M | -66.82M |
| TaxProvision | 8.15M | 3.19M | 959.00K | 239.00K |
| PretaxIncome | -207.18M | -151.75M | -130.24M | -66.58M |
| OtherIncomeExpense | 34.10M | -9.71M | 27.08M | 23.53M |
| OtherNonOperatingIncomeExpenses | 1.06M | -1.14M | ||
| GainOnSaleOfSecurity | 34.10M | -9.71M | 26.02M | 24.66M |
| NetNonOperatingInterestIncomeExpense | 30.79M | 14.51M | 2.72M | -129.00K |
| TotalOtherFinanceCost | -30.79M | -14.51M | -2.72M | 129.00K |
| InterestExpenseNonOperating | 129.00K | |||
| InterestIncomeNonOperating | 2.72M | |||
| OperatingIncome | -272.07M | -156.55M | -160.04M | -89.98M |
| OperatingExpense | 308.20M | 200.49M | 201.62M | 139.08M |
| ResearchAndDevelopment | 225.37M | 140.66M | 149.42M | 98.19M |
| SellingGeneralAndAdministration | 82.83M | 59.84M | 52.20M | 40.90M |
| GeneralAndAdministrativeExpense | 82.83M | 59.84M | 52.20M | 40.90M |
| OtherGandA | 82.83M | 59.84M | 52.20M | 40.90M |
| TotalRevenue | 36.13M | 43.95M | 41.59M | 49.11M |
| OperatingRevenue | 36.13M | 43.95M | 41.59M | 49.11M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 68.83M | 57.83M | 46.31M | 43.47M |
| ShareIssued | 68.83M | 57.83M | 46.31M | 43.47M |
| TotalDebt | 9.91M | 12.16M | 13.47M | 3.75M |
| TangibleBookValue | 646.25M | 354.54M | 245.10M | 313.85M |
| InvestedCapital | 647.93M | 356.34M | 247.06M | 316.20M |
| WorkingCapital | 482.00M | 299.73M | 227.52M | 352.28M |
| NetTangibleAssets | 646.25M | 354.54M | 245.10M | 313.85M |
| CapitalLeaseObligations | 9.91M | 12.16M | 13.47M | 3.75M |
| CommonStockEquity | 647.93M | 356.34M | 247.06M | 316.20M |
| TotalCapitalization | 647.93M | 356.34M | 247.06M | 316.20M |
| TotalEquityGrossMinorityInterest | 647.93M | 356.34M | 247.06M | 316.20M |
| StockholdersEquity | 647.93M | 356.34M | 247.06M | 316.20M |
| GainsLossesNotAffectingRetainedEarnings | -55.47M | -22.53M | -30.45M | -9.22M |
| OtherEquityAdjustments | -55.47M | -22.53M | -30.45M | -9.22M |
| RetainedEarnings | -968.39M | -753.06M | -598.12M | -466.93M |
| AdditionalPaidInCapital | 1.66B | 1.13B | 870.87M | 787.87M |
| CapitalStock | 6.96M | 5.88M | 4.75M | 4.48M |
| CommonStock | 6.96M | 5.88M | 4.75M | 4.48M |
| TotalLiabilitiesNetMinorityInterest | 134.77M | 99.15M | 129.49M | 140.40M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 47.69M | 30.06M | 50.56M | 68.50M |
| NonCurrentDeferredLiabilities | 39.48M | 19.57M | 38.77M | 66.24M |
| NonCurrentDeferredRevenue | 39.48M | 19.57M | 38.77M | 66.24M |
| LongTermDebtAndCapitalLeaseObligation | 8.21M | 10.49M | 11.79M | 2.26M |
| LongTermCapitalLeaseObligation | 8.21M | 10.49M | 11.79M | 2.26M |
| CurrentLiabilities | 87.08M | 69.09M | 78.93M | 71.90M |
| OtherCurrentLiabilities | 103.00K | 35.00K | 38.00K | 1.11M |
| CurrentDeferredLiabilities | 29.93M | 22.68M | 29.42M | 34.66M |
| CurrentDeferredRevenue | 29.93M | 22.68M | 29.42M | 34.66M |
| CurrentDebtAndCapitalLeaseObligation | 1.70M | 1.67M | 1.68M | 1.49M |
| CurrentCapitalLeaseObligation | 1.70M | 1.67M | 1.68M | 1.49M |
| PayablesAndAccruedExpenses | 55.34M | 44.70M | 47.79M | 34.63M |
| CurrentAccruedExpenses | 43.85M | 38.45M | 35.55M | 21.40M |
| Payables | 11.48M | 6.25M | 12.23M | 13.24M |
| TotalTaxPayable | 7.32M | 1.65M | 2.40M | 0.00 |
| IncomeTaxPayable | 7.32M | 1.65M | 2.40M | 0.00 |
| AccountsPayable | 4.16M | 4.60M | 9.83M | 13.24M |
| TotalAssets | 782.69M | 455.49M | 376.54M | 456.60M |
| TotalNonCurrentAssets | 213.62M | 86.68M | 70.10M | 32.42M |
| OtherNonCurrentAssets | 3.39M | 2.87M | 4.81M | 2.08M |
| NonCurrentDeferredAssets | 1.52M | 1.20M | 2.04M | 417.00K |
| NonCurrentDeferredTaxesAssets | 1.52M | 1.20M | 2.04M | 417.00K |
| InvestmentsAndAdvances | 187.01M | 57.31M | 36.46M | 20.30M |
| OtherInvestments | 36.46M | 20.30M | ||
| InvestmentinFinancialAssets | 187.01M | 57.31M | 36.46M | 20.30M |
| HeldToMaturitySecurities | 187.01M | 57.31M | 36.46M | |
| AvailableForSaleSecurities | 20.30M | |||
| GoodwillAndOtherIntangibleAssets | 1.68M | 1.80M | 1.95M | 2.35M |
| OtherIntangibleAssets | 1.68M | 1.80M | 1.95M | 2.35M |
| NetPPE | 20.02M | 23.50M | 24.84M | 7.28M |
| AccumulatedDepreciation | -9.49M | -7.74M | -5.18M | -4.42M |
| GrossPPE | 29.51M | 31.24M | 30.02M | 11.71M |
| Leases | 9.82M | 10.29M | 9.11M | 111.00K |
| ConstructionInProgress | 0.00 | 44.00K | 75.00K | 1.06M |
| OtherProperties | 17.75M | 18.85M | 18.97M | 9.32M |
| MachineryFurnitureEquipment | 1.94M | 2.05M | 1.87M | 1.22M |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 569.07M | 368.81M | 306.44M | 424.18M |
| OtherCurrentAssets | 1.02M | 727.00K | 2.20M | 2.17M |
| RestrictedCash | 700.00K | 800.00K | ||
| PrepaidAssets | 25.62M | 8.93M | 9.31M | 4.91M |
| Receivables | 4.71M | 3.98M | 4.70M | 6.67M |
| AccruedInterestReceivable | 3.45M | 1.55M | 647.00K | 367.00K |
| AccountsReceivable | 1.26M | 2.43M | 4.05M | 6.31M |
| CashCashEquivalentsAndShortTermInvestments | 537.03M | 354.38M | 290.23M | 410.43M |
| OtherShortTermInvestments | 243.73M | 150.13M | 142.48M | 168.99M |
| CashAndCashEquivalents | 293.29M | 204.25M | 147.75M | 241.44M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -187.66M | -146.19M | -157.54M | -60.50M |
| IssuanceOfCapitalStock | 457.48M | 225.94M | 57.74M | 265.11M |
| CapitalExpenditure | -1.83M | -3.98M | -7.64M | -870.00K |
| IncomeTaxPaidSupplementalData | 2.80M | 3.10M | 0.00 | 635.00K |
| EndCashPosition | 294.03M | 205.01M | 148.44M | 241.75M |
| BeginningCashPosition | 205.01M | 148.44M | 241.75M | 163.28M |
| EffectOfExchangeRateChanges | 1.07M | -4.28M | -4.95M | 2.76M |
| ChangesInCash | 87.95M | 60.86M | -88.36M | 75.70M |
| FinancingCashFlow | 494.01M | 230.09M | 58.74M | 281.95M |
| CashFlowFromContinuingFinancingActivities | 494.01M | 230.09M | 58.74M | 281.95M |
| NetOtherFinancingCharges | -325.00K | -445.00K | -214.00K | -575.00K |
| ProceedsFromStockOptionExercised | 36.86M | 4.59M | 1.21M | 17.42M |
| NetCommonStockIssuance | 457.48M | 225.94M | 57.74M | 265.11M |
| CommonStockIssuance | 457.48M | 225.94M | 57.74M | 265.11M |
| InvestingCashFlow | -220.22M | -27.02M | 2.80M | -146.62M |
| CashFlowFromContinuingInvestingActivities | -220.22M | -27.02M | 2.80M | -146.62M |
| NetInvestmentPurchaseAndSale | -218.39M | -23.04M | 10.44M | -145.75M |
| SaleOfInvestment | 191.80M | 212.22M | 230.17M | 70.09M |
| PurchaseOfInvestment | -410.19M | -235.26M | -219.72M | -215.84M |
| NetIntangiblesPurchaseAndSale | -163.00K | 0.00 | -52.00K | 0.00 |
| PurchaseOfIntangibles | -163.00K | 0.00 | -52.00K | 0.00 |
| NetPPEPurchaseAndSale | -1.67M | -3.98M | -7.59M | -870.00K |
| PurchaseOfPPE | -1.67M | -3.98M | -7.59M | -870.00K |
| OperatingCashFlow | -185.84M | -142.21M | -149.90M | -59.63M |
| CashFlowFromContinuingOperatingActivities | -185.84M | -142.21M | -149.90M | -59.63M |
| ChangeInWorkingCapital | 24.32M | -25.75M | -18.97M | 15.87M |
| ChangeInOtherWorkingCapital | 30.95M | -27.81M | -25.18M | 9.11M |
| ChangeInPayablesAndAccruedExpense | 13.27M | -2.32M | 11.73M | 12.84M |
| ChangeInAccruedExpense | 13.40M | 1.61M | 15.65M | 2.13M |
| ChangeInPayable | -136.00K | -3.93M | -3.92M | 10.71M |
| ChangeInAccountPayable | -136.00K | -3.93M | -3.92M | 10.71M |
| ChangeInPrepaidAssets | -20.97M | 2.65M | -7.34M | -1.09M |
| ChangeInReceivables | 1.07M | 1.73M | 1.83M | -4.99M |
| ChangesInAccountReceivables | 1.07M | 1.73M | 1.83M | -4.99M |
| StockBasedCompensation | 45.83M | 26.23M | 24.54M | 17.09M |
| AmortizationOfSecurities | -4.46M | -5.07M | -407.00K | 450.00K |
| DeferredTax | -321.00K | 842.00K | -1.62M | -7.00K |
| DeferredIncomeTax | -321.00K | 842.00K | -1.62M | -7.00K |
| DepreciationAmortizationDepletion | 2.47M | 2.54M | 1.28M | 1.49M |
| DepreciationAndAmortization | 2.47M | 2.54M | 1.28M | 1.49M |
| AmortizationCashFlow | 177.00K | 215.00K | 304.00K | 240.00K |
| AmortizationOfIntangibles | 177.00K | 215.00K | 304.00K | 240.00K |
| Depreciation | 2.29M | 2.33M | 981.00K | 1.25M |
| OperatingGainsLosses | -38.34M | 13.95M | -23.53M | -27.70M |
| NetForeignCurrencyExchangeGainLoss | -38.34M | 13.95M | -23.53M | -27.70M |
| NetIncomeFromContinuingOperations | -215.33M | -154.94M | -131.19M | -66.82M |
SEC Filings
No SEC filings found for this symbol (may be non-US or ticker not in SEC index).
Public Trades for MRUS
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|